

**UNITED STATES PATENT AND TRADEMARK OFFICE**

---

**BEFORE THE PATENT TRIAL AND APPEAL BOARD**

---

**REGENERON PHARMACEUTICALS, INC.,**  
Petitioner

v.

**NOVARTIS PHARMA AG,**  
**NOVARTIS TECHNOLOGY LLC,**  
**NOVARTIS PHARMACEUTICALS CORPORATION,**  
Patent Owner

---

**Case IPR2020-01317 & IPR2020-1318**  
Patent 9,220,631

---

**DECLARATION OF KARL R. LEINSING, PE, IN SUPPORT OF**  
**NOVARTIS'S**  
**PATENT OWNER PRELIMINARY RESPONSE**

## TABLE OF CONTENTS

|       |  |    |
|-------|--|----|
| I.    | Introduction.....                                  | 1  |
| II.   | Background and Qualifications .....                | 1  |
| III.  | Summary of Opinions.....                           | 4  |
| IV.   | Legal Principles .....                             | 4  |
|       | A. Burden of Proof.....                            | 4  |
|       | B. Prior Art.....                                  | 5  |
|       | C. Obviousness.....                                | 5  |
|       | D. Reduction to Practice.....                      | 8  |
| V.    | The '631 Patent.....                               | 9  |
| VI.   | Person of Ordinary Skill in the Art.....           | 11 |
| VII.  | Analysis of Prior Art Relied on by petitioner..... | 12 |
|       | A. Sigg.....                                       | 12 |
|       | B. Boulange.....                                   | 18 |
|       | C. Lam.....  | 25 |
|       | D. Reuter .....                                    | 27 |
| VIII. | Analysis of 1317 Obviousness Arguments.....        | 30 |

|     |   |    |
|-----|---|----|
| A.  | A POSA Would Not Have Been Motivated to Combine Sigg<br>and Boulange to Make a Prefilled Syringe Filled with a VEGF<br>Antagonist for Intravitreal Injection..... | 31 |
| B.  | A POSA Would Not Have Reasonably Expected a PFS<br>Combining Sigg and Boulange to Succeed.....  | 39 |
| IX. | Analysis of 1318 Obviousness Arguments.....   | 44 |
| A.  | A POSA would not have been Motivated to Combine Lam and<br>Reuter to arrive at a PFS containing less than about 100 µg<br>silicone oil .....                      | 45 |
| B.  | A POSA would not have Reasonably Expected to Successfully<br>Combine Lam and Reuter to Lower Silicone Oil Levels Below<br>About 100 µg.....                       | 49 |
| X.  | The Inventions Claimed in the '631 Patent Were Constructively<br>Reduced to Practice in EP '649 and the '352 Application .....                                    | 50 |
| XI. | Declaration.....  | 70 |

## **I. INTRODUCTION**

1. I, Karl R. Leinsing, MSME, PE, submit this declaration on behalf of Novartis Pharma AG, Novartis Technology LLC, and Novartis Pharmaceuticals Corp. (collectively, “Patent Owner” or “Novartis”), regarding IPR2020-1317 and IPR2020-1318. I understand that Regeneron Pharmaceuticals, Inc. (“Petitioner” or “Regeneron”) initiated these proceedings by filing Petitions seeking cancellation of all claims of U.S. Patent No. 9,220,631 (“the ’631 patent”).

2. The subject of my declaration is the validity of the ’631 patent. This declaration is the result of my review and analysis of the petitions, declarations, and prior art submitted by the Petitioner in the above referenced IPR proceedings, as well as additional materials identified herein.

## **II. BACKGROUND AND QUALIFICATIONS**

3. I received a Bachelor of Science (B.S.) degree in mechanical engineering from the University of New Hampshire in 1988 and a Master of Science (M.S.) degree in mechanical engineering from North Carolina A&T State University in 1995. I am also licensed as a Registered Professional Engineer in the state of New Hampshire.

4. I have been a medical device engineer since 1992 and worked extensively with medical device disposables, including syringes of all types, since that date. I have extensive expertise in the mechanical design and manufacturing

of medical devices. My areas of expertise include full life-cycle product development of medical devices, including conception, patent applications, manufacturing, testing, verification, validation, packaging, bioburden testing, sterility assurance testing, biocompatibility, bacterial contamination testing, labeling, clinical trials, regulatory approval, marketing, and sales training.

5. Since 2006, I have been President of ATech Designs, Inc., where I have worked in the development of various medical devices, including cardiovascular, surgical, intravenous, endoluminal, and percutaneous devices. More specifically, I have consulted in the development of various drug delivery devices, such as auto-injectors, pen injectors, syringes, safety syringes, and insulin pumps, among others.

6. Previously, from 2005 to 2006, I worked as a Director of Biomedical Engineering at Mitralign, Inc., developing implants for heart valve repair. From 2002 to 2005, I worked as a Manager of Design Engineering at ONUX Medical, Inc., developing fixation devices for abdominal aortic aneurysm repair.

7. From 1992 to 2002, I worked as a Senior Principal Design Engineer at IVAC, which was a subsidiary of Eli Lilly & Company. There, I developed a number of medical drug infusion products, including disposable sets and components, IV and syringe pump systems, injection systems, vial adapters, syringes, and needle-free valves for the delivery of drugs. My work involved both

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.